company background image
AMPH logo

Amphastar Pharmaceuticals NasdaqGS:AMPH Stock Report

Last Price

US$38.70

Market Cap

US$1.9b

7D

3.6%

1Y

-31.7%

Updated

15 Jul, 2024

Data

Company Financials +

Amphastar Pharmaceuticals, Inc.

NasdaqGS:AMPH Stock Report

Market Cap: US$1.9b

AMPH Stock Overview

A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.

AMPH fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance6/6
Financial Health3/6
Dividends0/6

Amphastar Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amphastar Pharmaceuticals
Historical stock prices
Current Share PriceUS$38.70
52 Week HighUS$67.66
52 Week LowUS$36.56
Beta0.79
11 Month Change-4.42%
3 Month Change-5.38%
1 Year Change-31.73%
33 Year Change93.31%
5 Year Change101.25%
Change since IPO286.61%

Recent News & Updates

Recent updates

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 05
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Jul 01

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

May 30

Reassessing Amphastar Pharmaceuticals

May 15

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18
Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03
An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Mar 02
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Feb 07
Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Jan 24
Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 02
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Amphastar: A Pharmaceutical Growth Stock

Oct 06

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Aug 16

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Aug 08

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 24
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar generic vasopressin for increasing blood pressure gets FDA approval

Jul 19

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Jun 10
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio

May 13

I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

Apr 23
I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Feb 13
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Shareholder Returns

AMPHUS PharmaceuticalsUS Market
7D3.6%3.0%1.2%
1Y-31.7%26.5%22.0%

Return vs Industry: AMPH underperformed the US Pharmaceuticals industry which returned 26.5% over the past year.

Return vs Market: AMPH underperformed the US Market which returned 22% over the past year.

Price Volatility

Is AMPH's price volatile compared to industry and market?
AMPH volatility
AMPH Average Weekly Movement3.9%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement5.8%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: AMPH has not had significant price volatility in the past 3 months.

Volatility Over Time: AMPH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19961,761Jack Zhangwww.amphastar.com

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.

Amphastar Pharmaceuticals, Inc. Fundamentals Summary

How do Amphastar Pharmaceuticals's earnings and revenue compare to its market cap?
AMPH fundamental statistics
Market capUS$1.89b
Earnings (TTM)US$154.69m
Revenue (TTM)US$676.21m

12.2x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMPH income statement (TTM)
RevenueUS$676.21m
Cost of RevenueUS$308.83m
Gross ProfitUS$367.38m
Other ExpensesUS$212.69m
EarningsUS$154.69m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.16
Gross Margin54.33%
Net Profit Margin22.88%
Debt/Equity Ratio88.3%

How did AMPH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.